Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation (2021 - 2025)

Amylyx Pharmaceuticals' Accumulated Depreciation history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 14.35% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (up 14.35% YoY), while the FY2025 annual figure was $1.6 million, up 14.35% from the prior year.
• Accumulated Depreciation was $1.6 million for Q4 2025 at Amylyx Pharmaceuticals, up from $1.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $1.6 million in Q4 2023 to a low of $53000.0 in Q4 2021.
• Historically, Accumulated Depreciation has averaged $1.0 million across 5 years, with a median of $1.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accumulated Depreciation jumped 918.87% in 2022, then fell 16.52% in 2024.
• A 5-year view of Accumulated Depreciation shows it stood at $53000.0 in 2021, then surged by 918.87% to $540000.0 in 2022, then surged by 201.48% to $1.6 million in 2023, then decreased by 16.52% to $1.4 million in 2024, then rose by 14.35% to $1.6 million in 2025.
• The last three Accumulated Depreciation figures came in at $1.6 million (Q4 2025), $1.4 million (Q4 2024), and $1.6 million (Q4 2023), per Business Quant data.